Get an in-depth look at the impact of influenza A virus in swine (IAV-S) on growing pigs and current management strategies aimed to reduce IAV-S transmission.
Respiratory Coinfections and the Impact on Herd Productivity
Respiratory coinfections are a combination of infectious agents and environmental stressors and challenges that affect the health of the pig, reducing performance, increasing medication costs and mortality, and ultimately resulting in significant economic losses.1
Read more about the impact of respiratory coinfections
Case Study: Control of IAV-S Using Ingelvac Provenza® in a Whole-Herd Approach
In 2019, Dr. Clayton Johnson, a veterinarian with Carthage Veterinary Service, partnered with Boehringer Ingelheim to put a whole-herd approach to the test in a 6000 sow, closed-herd gilt multiplier with endemic IAV-S. Early results suggest the farm has controlled endemic IAV-S within the herd.
Read more about controlling endemic disease with a whole-herd approach
The Importance of Vaccination in Controlling Transmission of Influenza A Virus in Swine (IAV-S)
In order to properly control IAV-S, we must understand the way in which it is transmitted -both directly and indirectly- and the risks it poses to all swine herds.
Read more about understanding transmission for better control of IAV-S
Healthy Habits for Control of Influenza A Virus in Swine
A whole-herd approach to IAV-S control can reduce the impact of IAV-S in young pigs. The practice of healthy habits during the growing period aims to minimize the exposure of pigs to resident and novel IAV-S strains.
Read more about how healthy habits work together to support a whole-herd approach
Influenza A virus in swine (IAV-S) requires a whole-herd approach
What is a whole-herd approach? A control plan to reduce IAV-S endemicicity and its impact, from farrowing to finishing.
Read more about a whole-herd approach and the role of Ingelvac Provenza® in IAV-S control
Support Pig Performance With Broad Cross-Protection Against IAV-S
Ingelvac Provenza®, now indicated for vaccination against influenza H1N1, H1N2, and H3N2, provides a strong foundation for respiratory health.
Read more about broad cross-protection
Managing IAV-S: New Data Show Significant Improvement in Average Daily Gain (ADG) and Mortality
Studies have shown that vaccination with Ingelvac Provenza® can be a valuable tool in current IAV-S protocols with a positive vaccine impact measured by standard performance targets.
Read more about building a strong immune foundation throughout the herd
A Valuable Tool to Protect Against Influenza A Virus in Swine (IAV-S)
The use of key performance indicators, including average daily gain (ADG) and variation (the spread of weights across a group of pigs), is essential in helping assess the success of IAV-S protocols. This in-field evaluation supports Ingelvac Provenza® as a strong foundation for respiratory health.
Read more about the positive impact on key performance measures with Ingelvac Provenza®
Pathogen Burden: IAV-S and the Impact on Growing Pigs
Growing pigs in the United States face the threat of numerous respiratory pathogens throughout their growing period, creating a significant impact on productivity and profitability.
Read more about pathogen burden through all production phases
Paradigm Shift: IAV-S in Pigs: Shifting the Approach to Protection
Once considered a seasonal, "simple" virus, influenza A virus in swine (IAV-S) has become an endemic dilemma with detrimental effect on performance and profitability. Ongoing IAV-S infection is not confined to the nursery; it impacts all phases of a swine operation, making it clear that traditional management strategies are no longer as effective or dependable as they once were.
Read more about individual protection for individual pigs
Industry Voice: A New Generation of Protection Against Influenza A Virus in Swine (IAV-S)
Posing a serious threat to performance, influenza A virus in swine (IAV-S) can have a widespread impact on productivity and profitability. IAV-S is one of the top three diseases affecting pigs in all phases of production,2,3 and can lead to economic losses of more than $10 per head when present with concurrent infections.4 It can also lead to subsequent respiratory infections that can impact pig performance, including mortality and culls.
Read more about the first live attenuated influenza vaccine for pigs